The application for investigational new drug (IND) and Clinical Trial Application (CTA) is a key step in initiating clinical trials/first-in-human (FIH) trials for a drug candidate. Furthermore, its approval can help companies secure additional funding and facilitate pipeline generation.
However, pre-clinical toxicology studies can present a bottleneck for companies on the path to FIH. Accelerating their timelines through rapid toxicology material delivery can be an effective way to reduce a drug candidate’s time to enter the clinic. Read more in the article.
You may also be interested in:
Latest content
Latest briefing from the Knowledge Center